Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

13.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
13.5K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

8.2K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
8.2K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.3K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.3K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

7.4K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
7.4K
Detailed Structure and Function of Lymph Nodes01:23

Detailed Structure and Function of Lymph Nodes

3.6K
Lymph nodes are bean-shaped structures that cluster along the lymphatic vessels in the inguinal, axillary, and cervical regions. Each node is divided into compartments by a capsule that extends trabeculae inward.
From a histological perspective, lymph nodes can be split into two main areas: the superficial cortex and the deep medulla. The outer cortex is populated by dendritic cells, macrophages, and B lymphocytes, which are densely packed into follicles. When these B-lymphocytes are presented...
3.6K
Lymphatic Vessels and Lymph Transport01:16

Lymphatic Vessels and Lymph Transport

21.3K
Lymphatic vessels, known as lymphatics, are crucial in transporting lymph from peripheral tissues to our venous system. This process begins with lymph entering through tiny capillaries that branch through tissues. These capillaries have unique features such as larger diameters, thinner walls, and a distinctive one-way valve system formed by overlapping endothelial cells.
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular...
21.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.

Journal of geriatric oncology·2026
Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026
Same author

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Leukemia·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Nov 20, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.3K

Classical Hodgkin lymphoma.

Pauline Brice1, Eric de Kerviler2, Jonathan W Friedberg3

  • 1Department of Oncohaematology, Hôpital saint Louis APHP, Université Paris 7, Paris, France.

Lancet (London, England)
|January 25, 2021
PubMed
Summary
This summary is machine-generated.

Classical Hodgkin lymphoma is a common cancer, often curable with chemotherapy. However, some patients are not cured, and others face long-term treatment side effects, impacting life years.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.5K

Related Experiment Videos

Last Updated: Nov 20, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.5K

Area of Science:

  • Oncology
  • Hematology
  • Cancer Research

Background:

  • Classical Hodgkin lymphoma (cHL) is a frequent hematologic malignancy.
  • Standard first-line chemotherapy and radiotherapy offer high cure rates for cHL.
  • Unresolved issues include treatment resistance and long-term therapy toxicities.

Purpose of the Study:

  • To review the current challenges in classical Hodgkin lymphoma treatment.
  • To discuss the impact of late toxic effects on patient survival.
  • To highlight recent advancements, including immunotherapy in relapsed settings.

Main Methods:

  • Review of current literature on classical Hodgkin lymphoma.
  • Analysis of treatment outcomes and late toxicities.
  • Examination of emerging therapeutic strategies.

Main Results:

  • Despite high cure rates, a subset of patients remains refractory to front-line therapy.
  • Premature mortality in cured patients is often attributed to late treatment-related toxicities.
  • Immunotherapy has emerged as a significant option, particularly for relapsed or refractory disease.

Conclusions:

  • Addressing treatment resistance and mitigating long-term toxicities are critical for improving outcomes in classical Hodgkin lymphoma.
  • The evolving treatment landscape, including immunotherapy, offers new hope for patients with relapsed disease.
  • Optimizing therapy to balance cure rates with long-term quality of life remains a key objective.